IsoRay Inc. (NYSEMKT:ISR) shares rose Monday, after the medical-technology company said its first Cesium-131 seed was shipped to Peru the treatment of a Glioma brain tumor located near the brainstem, and was successfully implanted by neurosurgeon Carlos Alvarez.

The seed was implanted in a 7-year-old female diagnosed with a 3-centimeter inoperable Glioma brain tumor that was positioned close to the brainstem, the company said. According to Alvarez, due to the size and tumor location, surgery and high dose radiation using radiosurgery weren’t an option. Following the procedure, Alvarez reported there were no postoperative complications and the young girl was awake with no additional neurological deficit. ISR was up 8.4% at $2.97 recently, in a 52-week range of $0.44 to $3.77.

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) American depositary shares edged higher Monday, as the therapeutic-drugs developer’s stock extended a recent climb from its 52-week low. The ascent comes as investors are returning to higher-risk industries as fears recede about the health of Portuguese banks.

The Australian company’s ADRs rose 0.8% to $2.63 in recent trading Monday. It reached a low of $1.47 during regular trading May 7 and has been on a fairly steady climb since then. Prana had plunged 72% on March 31 after its experimental treatment for Alzheimer’s disease, PBT2, failed to help patients in a study.

Kaman Corporation (NYSE:KAMN) said it has won a contract modification worth $8.5 million for the procurement of joint programmable fuzes from the U.S. Air Force. The maker of aircraft bearings and components said the contract is a follow-on order that raises the total under Option 11 of its contract for joint programmable fuzes with the U.S. Air Force to about $50.4 million. The delivery of the fuzes is expected to occur in 2015 and 2016. KAN was up 1.1% at $42.50 recently, in the upper half of its 52-week range between $34.87 and $44.60.

Get Free Updates and Stock Alerts!

*We only send one email per week